Merus is using its Biclonics technology platform ... mechanism to effectively block oncogenic signaling through the HER2:HER3 heterodimer even under high heregulin concentrations.
In preclinical studies, Merus has observed that Zeno is capable of potent inhibition of neuregulin-driven HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.
MedPage Today on MSN3mon
FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung CancersThe FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.
HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback